

ASX RELEASE

ADMEDUS TO HOST SHAREHOLDER WEBINAR

- Admedus shareholder webinar Tuesday, 28 February 2017
- 12pm AEDT Sydney/Melbourne; 11am AEST Brisbane; 9am AWST Perth

Brisbane, Australia 16 February 2017

Admedus (ASX:AHZ) today announced that it will hold a shareholder webinar on Tuesday, 28 February 2017 to discuss the outcome of the Company's restructure to date and half yearly results.

The webinar will be presented by the Company's Chairman and Interim CEO, Mr. Wayne Paterson, and will address Admedus' business progress and performance.

The webinar will be live and shareholders are welcome to submit questions in the lead up to the webinar to: info@admedus.com

Webinar details:

Date: Tuesday, 28 February 2017

Time: 12pm AEDT Sydney/Melbourne; 11am AEST Brisbane; 9am AWST Perth

Please register to attend the seminar at:

<https://attendee.gotowebinar.com/register/4459538179101828354>

Once you have registered to attend the webinar via the link above, you will receive a confirmation email with the webcast link and dial-in details.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

Website: www.admedus.com

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

Signal Leadership Communication Inc.

Mr Bob Pickard

Tel: +1 (647) 822 1000

bob.pickard@signaleadership.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC
Melody A. Carey
+1 917 322 2571
mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com